Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biotechnology company, has scheduled its fourth quarter 2024 financial results conference call and webcast for Thursday, March 27, 2025, at 4:30 PM ET. The company will discuss its business progress and financial performance for the quarter ended December 31, 2024.
Investors can access the conference through US dial-in (1-877-407-0792) or International dial-in (1-201-689-8263) with conference code 13751458. A webcast replay will be available in the Investors section of Relmada's website.
Relmada Therapeutics (NASDAQ: RLMD), una compagnia biotecnologica in fase clinica, ha programmato la sua conferenza sui risultati finanziari del quarto trimestre 2024 per giovedì 27 marzo 2025, alle 16:30 ET. L'azienda discuterà dei progressi aziendali e delle performance finanziarie per il trimestre conclusosi il 31 dicembre 2024.
Gli investitori possono accedere alla conferenza tramite il numero di chiamata USA (1-877-407-0792) o il numero internazionale (1-201-689-8263) utilizzando il codice conferenza 13751458. Una registrazione della webcast sarà disponibile nella sezione Investitori del sito web di Relmada.
Relmada Therapeutics (NASDAQ: RLMD), una empresa biotecnológica en etapa clínica, ha programado su conferencia sobre los resultados financieros del cuarto trimestre de 2024 para el jueves 27 de marzo de 2025, a las 4:30 PM ET. La compañía discutirá sus avances comerciales y el rendimiento financiero para el trimestre que finalizó el 31 de diciembre de 2024.
Los inversores pueden acceder a la conferencia a través del número de EE. UU. (1-877-407-0792) o del número internacional (1-201-689-8263) con el código de conferencia 13751458. Una repetición de la transmisión estará disponible en la sección de Inversores del sitio web de Relmada.
Relmada Therapeutics (NASDAQ: RLMD), 임상 단계의 생명공학 회사가 2025년 3월 27일 목요일 오후 4:30 ET에 2024년 4분기 재무 결과에 대한 컨퍼런스 콜 및 웹캐스트를 예정했습니다. 회사는 2024년 12월 31일로 종료된 분기의 사업 진행 상황과 재무 성과에 대해 논의할 것입니다.
투자자들은 미국 전화번호(1-877-407-0792) 또는 국제 전화번호(1-201-689-8263)를 통해 컨퍼런스에 접속할 수 있으며, 컨퍼런스 코드 13751458을 사용할 수 있습니다. 웹캐스트 재생은 Relmada의 웹사이트 투자자 섹션에서 제공될 것입니다.
Relmada Therapeutics (NASDAQ: RLMD), une entreprise de biotechnologie en phase clinique, a programmé sa conférence téléphonique et son webinaire sur les résultats financiers du quatrième trimestre 2024 pour jeudi 27 mars 2025 à 16h30 ET. L'entreprise discutera de ses progrès commerciaux et de ses performances financières pour le trimestre se terminant le 31 décembre 2024.
Les investisseurs peuvent accéder à la conférence par le numéro d'appel américain (1-877-407-0792) ou le numéro d'appel international (1-201-689-8263) avec le code de conférence 13751458. Un replay du webinaire sera disponible dans la section Investisseurs du site web de Relmada.
Relmada Therapeutics (NASDAQ: RLMD), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Telefonkonferenz und Webcast zu den finanziellen Ergebnissen des vierten Quartals 2024 für Donnerstag, den 27. März 2025, um 16:30 Uhr ET angesetzt. Das Unternehmen wird über seine Geschäftsentwicklung und finanzielle Leistung für das am 31. Dezember 2024 endende Quartal berichten.
Investoren können an der Konferenz über die US-Teilnehmernummer (1-877-407-0792) oder die internationale Teilnehmernummer (1-201-689-8263) mit dem Konferenzcode 13751458 teilnehmen. Eine Aufzeichnung des Webcasts wird im Investorenbereich der Relmada-Website verfügbar sein.
- None.
- None.
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024.
Conference Call and Webcast Information:
- Date: Thursday, March 27, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Conference: 13751458
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette’s Syndrome into further studies.
For more information, visit www.relmada.com.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When will Relmada Therapeutics (RLMD) release Q4 2024 earnings?
How can investors access RLMD's Q4 2024 earnings call?
Where can I find the replay of RLMD's Q4 2024 earnings webcast?
What period will RLMD's upcoming earnings report cover?
